Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Update

Key Points

• Short interest fell 65.5% to 25,053 shares as of August 31, representing approximately 0.0% of outstanding shares and a short-interest ratio of 1.4 days.
• Analyst sentiment was mixed: three analysts rated Pharming Group a Buy and two rated it a Sell, resulting in an overall “Hold” consensus and an average price target of $38.67.
• Pharming Group reported quarterly EPS of $0.02, missing the $0.06 consensus estimate. The company had a 2.51% net margin, 3.40% return on equity, and analysts projected full-year EPS of $0.25.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) was the recipient of a significant decrease in short interest in August. As of August 31st, there was short interest totaling 25,053 shares, a decrease of 65.5% from the August 15th total of 72,693 shares. Approximately 0.0% of the company's stock are short sold. Based on an average trading volume of 17,420 shares, the short-interest ratio is currently 1.4 days.

Analyst Upgrades and Downgrades

PHAR has been the subject of several recent analyst reports. Oppenheimer reissued an "outperform" rating on shares of Pharming Group in a report on Thursday, July 30th. Canaccord Genuity Group upped their target price on shares of Pharming Group from $37.00 to $38.00 and gave the company a "buy" rating in a research note on Monday, August 3rd. Zacks Research cut shares of Pharming Group from a "hold" rating to a "strong sell" rating in a research report on Friday, July 31st. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of Pharming Group in a research note on Friday, August 7th. Three investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the company has an average rating of "Hold" and a consensus price target of $38.67.

Pharming Group Stock Up 3.7%

Shares of Pharming Group stock opened at $11.21 on Friday. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.01 and a quick ratio of 2.31. Pharming Group has a 1-year low of $9.62 and a 1-year high of $21.34. The business's fifty day moving average price is $12.07 and its two-hundred day moving average price is $13.86. The company has a market capitalization of $793.42 million, a P/E ratio of 93.42 and a beta of 0.01.

Pharming Group (NASDAQ:PHAR - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.06 by ($0.04). Pharming Group had a return on equity of 3.40% and a net margin of 2.51%. As a group, research analysts forecast that Pharming Group will post 0.25 EPS for the current year.

Hedge Funds Weigh In On Pharming Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in PHAR. EverSource Wealth Advisors LLC bought a new stake in shares of Pharming Group in the 2nd quarter worth $32,000. SmartHarvest Portfolios LLC acquired a new position in Pharming Group during the fourth quarter worth about $224,000. Millennium Management LLC bought a new stake in Pharming Group in the fourth quarter worth about $360,000. Finally, NewEdge Advisors LLC raised its position in Pharming Group by 11,310.3% in the fourth quarter. NewEdge Advisors LLC now owns 28,868 shares of the company's stock worth $510,000 after acquiring an additional 28,615 shares in the last quarter. 0.03% of the stock is owned by institutional investors.

Pharming Group Company Profile

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company's lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.